Lisa D. Beilke, MSPH, PhD, DABT, Fellow ATS
Head of Toxicology

Dr. Beilke has over 25 years of experience working in various fields of toxicology in support of small and large molecule therapeutics. She has worked for small contract laboratories, start-up biotechs, as well as large pharma (Pfizer, Gilead). She earned her PhD in Pharmacology & Toxicology from the University of Arizona, as well as her BS and MS (Public Health/Toxicology) degrees from San Diego State University. Dr. Beilke has been an independent consultant with Toxicology Solutions, Inc. since 2012 and has focused on providing toxicology services to the pharmaceutical industry, with a specialty in in silico toxicity predictions for potential genotoxic impurities and risk assessment. As a consultant, Dr. Beilke has worked with clients on various therapeutic areas (oncology, metabolic diseases, cardiovascular, etc.) and compound types (e.g., peptides, polymers, antibodies, dye conjugates, etc.).

Dr. Beilke has a long history of involvement with various toxicology organizations. She has been a member of the ACT since 1999 and has served on the Education (2009-2011) and Finance Committees (2011-2014), Councilor (2016-2018), and was presented with the Young Investigator award in 2013. She is also on the Editorial Board of the International Journal of Toxicology (2013-present). She is a full member of the SOT, where she served as President Elect, President, and Past President of the Computational Toxicology Specialty Section (CTSS), which she co-developed as a new Specialty Section. Dr. Beilke participated as a Councilor for the Roundtable of Toxicology Consultants (2024-2026) and was recently elected to the Nominating Committee for the ATS.